Contact Us
|
Data Center Logon
|
Site Tools
| Search
GO
Home
About Us
Welcome
History
Mission Statement
Headquarters Information
RTOG Headquarters Hours
Site Participation Materials
RTOG Password Application
Contact Us
NRG Oncology Information
Patients
Welcome
Links
Clinical Trial Resources
Patient Advocacy Groups
NIH
RTOG Informational Brochure
Clinical Trials
Welcome
Protocol Table
RTOG Foundation Studies
Non-Study Specific Forms
Active Study Accrual List
Broadcasts
Data Monitoring Committee (DMC)
Publications
Publications Update
Core Lab
Active Downloads
Advanced Technology Radiation Therapy
Contouring Atlases
Anorectal
Bladder Atlas
Brachial Plexus Contouring Atlas
Breast Cancer Atlas
Female RTOG Normal Pelvis Atlas
GYN
H & N Atlases
Hippocampal Sparing
Male RTOG Normal Pelvis Atlas
Pancreas Atlas
Prostate Pelvic Lymph Nodes
Prostate Post-Op
RTOG Extremity Soft Tissue Sarcoma Atlas
Lung Atlas
Upper Abdominal Normal Organ Contouring Consensus
RADCOMP Breast Atlas
Vulvar Cancer Atlas
Standardized Naming Conventions
RTQA Protocol Prescription Guidelines
Approval Process
Education/Training
Advanced Imaging
MRI/CT Core Lab Information
PET Core Lab Information
Contact RTQA
TRIAD
Researchers
Welcome
Policies & Manuals
Procedures Manual
Conflict of Interest Policy
Scientific Misconduct Policy
Data Sharing
Publication Guidelines
Broadcasts
Research Associates
Welcome
Education/Training
VisionTree Training
RA Education Materials
Adverse Event Reporting
Regulatory Information
CTSU Filing Requirements
Investigator Brochure Archive
Guidance Documents
Early IRB Closure
External Safety Reports
ABT-888
AMG 386
Bevacizumab
Cediranib
Crizotinib
Erlotinib
Everolimus
Ipilimumab
Lapatinib
Nivolumab
Panitumumab
Pazopanib
Sorafenib
TAK-700
Trastuzumab
Procedures
Lost to Follow-up
Patient Transfers
News
NRG Oncology Newsletters
RTOG Newsletter Archive
Welcome
Education/Training
Adverse Event Reporting
Regulatory Information
Procedures
Lost to Follow-up
Patient Transfers
Research Associates
>
Procedures
>
Patient Transfers
Patient Transfers
The
Patient Transfer Form
must be completed in order to authorize the transfer a patient from one NRG
Oncology
member institution to another. IRB approval for the protocol(s) at the recipient institution must be on file. Transfers between Lead Protocol Organizations are not permitted. This form must be signed by the institutional Principal Investigator at the institution where the patient was originally registered on study and by the Principal Investigator at the recipient institution. The completed form is submitted by the original PI to Clinical Trials Administration. Before the transfer is completed, both investigators should review the caveats to transfer, described in the
RTOG Procedure Manual
. Upon receipt of the form, the Legacy RTOG records and database are changed to reflect that the recipient institution is responsible for the case. Upon completion of the transfer, Administration signs a confirmation of the change with a copy sent to each investigator. Please note that it may take up to one week for the transfer to be completed once the form is submitted to Headquarters.
Patient Transfer Form
Copyright (c) 2019 RTOG
|
Privacy Statement
|
Login
RTOG is a participant in National Cancer Institute research through NRG Oncology.